Revive Therapeutics Ltd.

CNSX: RVV


Canadian symbol: RVV.CN
US symbol: RVVTF

Currency in CAD

Valuation Measures

Market Cap (intraday) 5106.28M
Enterprise Value 3103.63M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)10.79
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 7-10.11

Trading Information

Stock Price History

Beta (5Y Monthly) 0.20
52-Week Change 3159.38%
S&P500 52-Week Change 343.61%
52 Week High 30.9200
52 Week Low 30.1600
50-Day Moving Average 30.4736
200-Day Moving Average 30.4728

Share Statistics

Avg Vol (3 month) 31.16M
Avg Vol (10 day) 3342.41k
Shares Outstanding 5259.22M
Implied Shares Outstanding 6N/A
Float 254.07M
% Held by Insiders 12.04%
% Held by Institutions 11.55%
Shares Short (Apr. 14, 2021) 4631.78k
Short Ratio (Apr. 14, 2021) 41.12
Short % of Float (Apr. 14, 2021) 4N/A
Short % of Shares Outstanding (Apr. 14, 2021) 40.24%
Shares Short (prior month Mar. 14, 2021) 41.17M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Jun. 29, 2020
Most Recent Quarter (mrq)Dec. 30, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-106.50%
Return on Equity (ttm)-226.22%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -10.25M
Net Income Avi to Common (ttm)-11.7M
Diluted EPS (ttm)-0.0630
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)4.38M
Total Cash Per Share (mrq)0.02
Total Debt (mrq)432.58k
Total Debt/Equity (mrq)4.39
Current Ratio (mrq)10.42
Book Value Per Share (mrq)0.04

Cash Flow Statement

Operating Cash Flow (ttm)-4.3M
Levered Free Cash Flow (ttm)-1.94M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Psychedelics News and Psilocybin Investing

Real-time news from hundreds of sources. Never miss the news that matters the most.




Company News Date
RVV.CN
Revive Therapeutics
3 weeks ago
RVV.CN
Revive Therapeutics
3 weeks ago
RVV.CN
Revive Therapeutics
3 weeks ago
RVV.CN
Revive Therapeutics
4 months ago
RVV.CN
Revive Therapeutics
4 months ago
RVV.CN
Revive Therapeutics
4 months ago
RVV.CN
Revive Therapeutics
5 months ago
RVV.CN
Revive Therapeutics
5 months ago
RVV.CN
Revive Therapeutics
5 months ago
RVV.CN
Revive Therapeutics
5 months ago
RVV.CN
Revive Therapeutics
6 months ago
RVV.CN
Revive Therapeutics
6 months ago
RVV.CN
Revive Therapeutics
6 months ago
RVV.CN
Revive Therapeutics
6 months ago
RVV.CN
Revive Therapeutics
6 months ago
RVV.CN
Revive Therapeutics
6 months ago
RVV.CN
Revive Therapeutics
6 months ago
RVV.CN
Revive Therapeutics
6 months ago
RVV.CN
Revive Therapeutics
6 months ago
RVV.CN
Revive Therapeutics
6 months ago
RVV.CN
Revive Therapeutics
6 months ago
RVV.CN
Revive Therapeutics
7 months ago
RVV.CN
Revive Therapeutics
7 months ago
RVV.CN
Revive Therapeutics
8 months ago
RVV.CN
Revive Therapeutics
8 months ago
RVV.CN
Revive Therapeutics
8 months ago
RVV.CN
Revive Therapeutics
8 months ago
RVV.CN
Revive Therapeutics
8 months ago
RVV.CN
Revive Therapeutics
8 months ago
RVV.CN
Revive Therapeutics
8 months ago
RVV.CN
Revive Therapeutics
9 months ago
RVV.CN
Revive Therapeutics
9 months ago
RVV.CN
Revive Therapeutics
9 months ago
RVV.CN
Revive Therapeutics
9 months ago
RVV.CN
Revive Therapeutics
10 months ago
RVV.CN
Revive Therapeutics
10 months ago
RVV.CN
Revive Therapeutics
10 months ago
RVV.CN
Revive Therapeutics
11 months ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
2.04%% of Shares Held by All Insider
1.55%% of Shares Held by Institutions
1.58%% of Float Held by Institutions
9Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Gofen & Glossberg LLC150,000Mar. 30, 20210.21%72,750
tru Independence LLC80,000Dec. 30, 20200.11%49,600
FNY Investment Advisers, LLC25,000Mar. 30, 20210.03%12,125
HighPoint Advisor Group LLC15,996Mar. 30, 20210.02%7,758
Ifp Advisors, Inc5,000Mar. 30, 20210.01%2,425
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Revive Therapeutics Ltd.


Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional Patent Application

TORONTO, April 22, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the successful completion of the research results and filing of a U.S. provisional pa... Read More...

Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application

TORONTO, March 19, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce positive results of a pre-clinical study evaluating the efficacy of psilocybin in the... Read More...

SEMI Applauds President Biden, Bipartisan Congressional Leaders for Supporting Semiconductor Supply Chain Incentives

VANCOUVER, BC, Jan. 21, 2021 - The following issues have been halted by IIROC:Company: Revive Therapeutics Ltd.CSE Symbol: RVVAll Issues: YesReason: At the request of the Company Pending NewsHalt Time (ET): 7:47 AMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Tradi... Read More...

Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin

TORONTO, Jan. 14, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a sponsored research agreement and an exclusive option to license ... Read More...

Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study

TORONTO, Dec. 31, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. John Fahy, MD, MSc, as a Scientific and Clinical advisor to the... Read More...

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access

TORONTO, Dec. 23, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinica... Read More...

Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program

TORONTO, Dec. 21, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”), dated December 20... Read More...

Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor

TORONTO, Dec. 02, 2020 -- Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company... Read More...

PharmaTher Enters Into Research Collaboration with Revive Therapeutics for Psilocybin and panaceAI™ Psychedelic Discovery AI Platform

TORONTO, Nov. 18, 2020 -- PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce it has entered into an exclusive research collaboration agreement with Revive T... Read More...

Revive Therapeutics Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics

TORONTO, Nov. 18, 2020 -- Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into an exclusive research collaboration agreement with PharmaTher Inc., a wholly-owned ... Read More...

Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin

TORONTO, Nov. 11, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on its oral thin-film delivery system with psilocybin being developed under a... Read More...

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Oct. 26, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“U.S. FDA”) Phase 3 cl... Read More...

Don’t miss out on your BIG thanksgiving party – iotum offers “Free-for-All” Thanksgiving Free Conference service for the holiday weekend

VANCOUVER, BC, Aug. 19, 2020 - The following issues have been halted by IIROC:Company: Revive Therapeutics Ltd.CSE Symbol: RVVAll Issues: YesReason: At the request of the Company Pending NewsHalt Time (ET): 11:59 AMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trad... Read More...

Revive Therapeutics Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Sept. 29, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“U.S. FDA”) Phase 3 c... Read More...

Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs

TORONTO, Sept. 21, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide a corporate update on its psychedelics therapeutics programs specifically as it relates... Read More...

Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19

TORONTO, Sept. 16, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company’s expanded access protocol (“EAP”) for compassionate use of Bucillam... Read More...

Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder

TORONTO, Sept. 02, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company has entered into a Clinical Trial Agreement (CTA), dated August 28, ... Read More...

Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

TORONTO, Aug. 31, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company’s Phase 3 clinical trial protocol to evaluate the safety and efficacy... Read More...

Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

Revive to also explore FDA Expanded Access Program (Compassionate Use) for Bucillamine in COVID-19TORONTO, Aug. 26, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased ... Read More...

Revive Therapeutics to Expand Phase 3 Clinical Trial for Bucillamine in COVID-19 in Asia-Pacific and Canada

TORONTO, Aug. 19, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that following the U.S. Food & Drug Administration (“U.S. FDA”) approval to procee... Read More...

Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Aug. 14, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has signed a Memorandum of Understanding (“MOU”) with Attwill Medical Solutions... Read More...

Revive Therapeutics Update Following U.S. FDA Approval of Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Aug. 05, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that following the U.S. Food & Drug Administration (“U.S. FDA”) approval to procee... Read More...

UPDATE – Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, July 31, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV) (OTCQB: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food & Drug Administration (“U.S. FDA”) has approved the Company ... Read More...

Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, July 31, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food & Drug Administration (“U.S. FDA”) has approved the Company to proceed with... Read More...

Revive Therapeutics Expands Research Partnership for Novel Formulation Development and Clinical Research of Psilocybin with the University of Wisconsin-Madison

TORONTO, June 12, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an expansion to the sponsored research partnership agreement (“SRPA”) entered with the University ... Read More...

Revive Therapeutics Provides Update on Discussions with Health Canada in Pre-CTA Meeting

TORONTO, June 09, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company met with Health Canada in a Pre-Clinical Trial Application (“Pre-CTA”) meeting to ... Read More...

Revive Therapeutics Announces Filing of a Pre-CTA Meeting Request with Health Canada and Update on U.S. FDA IND Filing and Phase 3 Clinical Trial Design for Bucillamine in the Treatment of COVID-19

TORONTO, June 03, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has filed its Clinical Trial Application (“Pre-CTA”) with Health Canada and provides an upd... Read More...

Revive Therapeutics Provides an Update on its Psilocybin-Based Pharmaceutical Program

TORONTO, April 29, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide further insight on its plans for its psilocybin-based pharmaceutical program.  The Company will inv... Read More...

Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial

TORONTO, April 23, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has received positive feedback from the U.S. Food and Drug Administration (“FDA”) in response to ... Read More...

Revive Therapeutics Announces Research Partnership Agreement with the University of Wisconsin-Madison to Evaluate Novel Formulations and Drug Delivery Technology Focused on Psilocybin-Based Pharmaceuticals

TORONTO, April 21, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has entered into a sponsored research partnership agreement (“SRPA”) with the University of Wisco... Read More...

Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin-Based Pharmaceutical Products

TORONTO, April 17, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has engaged Complete Phytochemical Solutions, LLC., an internationally-recognized company specia... Read More...

Revive Therapeutics Announces Closing of Second Tranche of Brokered Private Placement

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREINTORONTO, April 15, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a life sciences company, is pleased to announce that further to its press releases of Februar... Read More...

Investor Announcement

TORONTO, April 03, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a life sciences company, has learnt that buy recommendations and letters are being circulated in Germany. The Company, along with the Federal Financial Supervisory Authority of Germany (“BaFin”) suggests shareholders fully understand these materials... Read More...

Revive Therapeutics Provides Corporate Update on its COVID-19 and Infectious Diseases Programs

TORONTO, March 30, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, is pleased to provide a corporate update on its plans for the Company’s coronavirus disease (“COVID-19”) and infectious disea... Read More...

Revive Therapeutics Engages Pharma-Olam and Strengthens Infectious Diseases Clinical Development Team to Advance U.S. FDA Clinical Study for COVID-19

TORONTO, March 25, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a life sciences company focused on the research and development of therapeutics for rare disorders and infectious diseases, is pleased to announce that the Company has retained Pharm-Olam, LLC, with proven clinical experience in infectious diseases ... Read More...

Revive Therapeutics Appoints Dr. David Boulware, MD, as Scientific Advisor for Infectious Diseases including COVID-19

TORONTO, March 24, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a life sciences company, is pleased to announce that Dr. David Boulware, MD, MPH, CTropMed, FIDSA, will join the Company as a Scientific Advisor to guide on the Company’s current and future clinical programs including its research and development st... Read More...

Revive Therapeutics Explores the Use of Bucillamine as a Novel Treatment for Infectious Diseases including COVID-19

TORONTO, March 20, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a life sciences company, is pleased to announce that it is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases including influenza and the coronavirus disease (COVID-19). The Company has applied for a pro... Read More...
Coming Soon.
SymbolExchangePriceChangeAs of
RVV.CD
Canadian Securities Exchange - CSE Listed
Canadian Securities Exchange - CSE Listed0.41CAD-1.20%
31R.F
Frankfurt Stock Exchange
Frankfurt Stock Exchange0.29EUR+1.40%
RVVTF.PK
US 'Other OTC' and Grey Market
US 'Other OTC' and Grey Market0.34USD+0.28%
RVV.CCP
Canadian Composite Quote/Trade
Canadian Composite Quote/Trade0.42CAD-3.49%
31R.BE
Berlin Stock Exchange
Berlin Stock Exchange0.28EUR-2.07%
31R.MU
Munich Stock Exchange
Munich Stock Exchange0.30EUR-3.69%
RVVTF.PQ
OTC MARKETS GROUP L1 AND L2
OTC MARKETS GROUP L1 AND L20.34USD+0.06%

Delayed data (1h)
NameAgePositionAppointed
Michael Frank
Chairman of the Board, Chief Executive Officer
--Chairman of the Board, Chief Executive Officer2019
Carmelo Marrelli
Chief Financial Officer, Secretary
--Chief Financial Officer, Secretary2015
Robbie Grossman
Director
--Director2015
Scott Johnson
Director
36Director--
Anton Konovalov
Director
26Director--
Andrew Lindzon
Director
--Director2019
Reiza Rayman
Director
53Director--
Christian Scovenna
Director
--Director2019


Share this page